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The tumor suppressor RhoBTB1 controls
Golgi integrity and breast cancer cell
invasion through METTL7B
Caroline M. McKinnon and Harry Mellor*
Abstract
Background: RhoBTB1 and 2 are atypical members of the Rho GTPase family of signaling proteins. Unlike other
Rho GTPases, RhoBTB1 and 2 undergo silencing or mutation in a wide range of epithelial cancers; however, little is
known about the consequences of this loss of function.
Methods: We analyzed transcriptome data to identify transcriptional targets of RhoBTB2. We verified these using Q-PCR
and then used gene silencing and cell imaging to determine the cellular function of these targets downstream of
RhoBTB signaling.
Results: RhoBTB1 and 2 regulate the expression of the methyltransferases METTL7B and METTL7A, respectively. RhoBTB1
regulates the integrity of the Golgi complex through METTL7B. RhoBTB1 is required for expression of METTL7B
and silencing of either protein leads to fragmentation of the Golgi. Loss of RhoBTB1 expression is linked to Golgi
fragmentation in breast cancer cells. Restoration of normal RhoBTB1 expression rescues Golgi morphology and
dramatically inhibits breast cancer cell invasion.
Conclusion: Loss of RhoBTB1 expression in breast cancer cells leads to Golgi fragmentation and hence loss of
normal polarity.
Keywords: Rho GTPases, RhoBTB1, BTB domain, Methyltransferase, Golgi fragmentation, Cell migration, Cell invasion
Background
The Rho GTPase family of signaling proteins are master
regulators of cell shape and cell migration. They do this
directly through dynamic regulation of the actin cyto-
skeleton; however, they also have diverse additional
cellular roles that contribute to this, including the con-
trol of membrane trafficking, cell polarity and gene ex-
pression [1]. The roles of Rho GTPases in cell migration
make them important signaling proteins in cancer. While
Rho GTPases are generally not direct targets of mutation
in cancer, their signaling pathways are frequently deregu-
lated, promoting the switch to cancer cell invasion and
metastasis [2, 3].
The human Rho GTPase family contains 20 mem-
bers, of which RhoA, Rac1 and Cdc42 are the best
characterized [4]. These are small, globular proteins
whose activity is controlled by binding of GTP, which
switches them into their active conformation. The Rho
family also contains two atypical members – RhoBTB1
and 2. These are larger, multimodular Rho GTPases
that have a conserved N-terminal Rho GTPase domain,
but also two copies of the BTB (Broad-Complex, Tram-
track and Bric a brac) domain and a carboxyl terminal
BACK (BTB and C-terminal Kelch) domain [5, 6]. Intri-
guingly, both genes undergo silencing or mutation in
human cancer. Hamaguchi and colleagues identified
RhoBTB2 in a representational difference analysis screen
for novel tumor suppressor genes in breast cancer, and
gave it the alternative name DBC2 (deleted in breast
cancer 2). The RhoBTB2/DBC2 gene undergoes homolo-
gous deletion in a relatively small number of breast tumor
samples; however, RhoBTB2 expression is silenced at high
frequency (approximately 50%) in breast and lung tumors
[7]. Subsequent studies have reported the silencing of
RhoBTB2 expression in a wide range of human tumors, as
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well as sporadic point mutations of the RhoBTB2 coding
region and promoter [8–11]. RhoBTB1 is 73% identical to
RhoBTB2 at the protein level. Far less is known about its
cellular functions; however, recent studies have shown
that it is also downregulated in human cancers. It is sub-
ject to loss of heterozygosity at high frequency in head
and neck squamous cell (HNSC) carcinomas [12] and its
expression is silenced in colon cancer through the actions
of the microRNA miR-31 [13].
Unlike the majority of members of the Rho GTPase
family, RhoBTB1 and 2 do not regulate the actin cyto-
skeleton directly [14]. Many proteins with BTB domains
function as transcription regulators [15] and in our pre-
vious studies we showed that this is also the case for
RhoBTB2 [16]. To determine transcription targets of
RhoBTB2, we silenced its expression in primary lung
epithelial cells and then performed whole-genome
microarray analysis of gene expression. This allowed us
to identify the chemokine CXCL14 as a target of
RhoBTB2 regulation [16]. CXCL14 expression is down-
regulated in a high percentage of carcinomas, and espe-
cially in HNSC carcinomas where its loss is correlated
with poor prognosis. Importantly, we found that loss of
RhoBTB2 expression is correlated with loss of CXCL14
expression in HNSC cancer cell lines, and that expres-
sion of the chemokine is rescued by re-expression of
RhoBTB2 [16].
CXCL14 was the most significant hit in the RhoBTB2
microarray screen; however, several other genes also
showed reduced expression upon RhoBTB2 silencing.
One of these was METTL7A, a poorly-characterized
methyltransferase enzyme. In this study, we investigate
the regulation of the METTL7 enzymes by RhoBTB pro-
teins and uncover a pathway controlling Golgi integrity
in mammary epithelial cells.
Methods
Materials
Full details of antibodies, oligonucleotides and plasmids
used in this study are given in Additional file 1.
Cell culture and transfection
HeLa, HEK293T, MDA-MB-231, MCF7 and T47D cells
were cultured in DMEM containing 10% heat-inactivated
fetal bovine serum. HMT-S1 and MCF10A cells were cul-
tured as previously described [17, 18]. HeLa cells were
transfected with plasmids and siRNA oligonucleotides
using calcium phosphate [16].
Real-time PCR
RNA was isolated from cells using the TRIzol extraction
method (Invitrogen) and 40 μg of purified RNA used for
reverse transcription using Omniscript RTase (Qiagen) for
1 h at 37 °C. cDNAs were then subjected to real-time PCR
using DyNAmo Flash SYBR Green (Finnzymes). Amplifi-
cation was performed using an Opticon 2 thermocycler
(MJ Research) and data was analyzed using the compara-
tive Ct method.
Immunofluorescence microscopy
Cells were fixed for 15 min in 4% paraformaldehyde in
PBS and then permeabilized in 0.2% Triton X-100 in
PBS for 5 min. Cells were then incubated with 0.1%
sodium borohydride for 10 min. Primary antibodies were
incubated with cells in 1% BSA for 1 h followed by
secondary antibodies for 45 min. The cells were stained
with 2 μg/ml DAPI for 10 min and mounted over
MOWIOL 4–88 (Calbiochem) containing 0.6% 1,4-
diazabicyclo-(2.2.2) octane as an anti-photobleaching
agent. Confocal microscopy was performed using a
Leica TCS-NT confocal laser-scanning microscope with
an attached Leica DMRBE upright epifluorescence micro-
scope under a PlanApo x63/1.32 oil-immersion objective.
A series of images were taken at 0.5 μm intervals through
the Z-plane of the cells and processed to form a projected
image.
Analysis of Golgi fragmentation
Fragmentation of the Golgi ribbon was scored blind in
cells stained for the Golgi marker giantin. Fifty cells were
scored from each condition to give the percentage of
cells with a fragmented Golgi. Data from three inde-
pendent experiments were processed to give the mean.
Re-expression of RhoBTB1
Expression of RhoBTB1 was restored in T47D cells by
stable integration of a lentiviral RhoBTB1 construct.
mCherry-tagged RhoBTB1 was subcloned into pHR’SIN-
cPPT-SEW [19]. Virus was generated by transfection of
HEK293T cells as described [19]. Briefly, 40 μg of RhoBTB1
vector was mixed with 10 μg of envelope plasmid pMDG,
30 μg of packaging plasmid psPAX2 and 1 μl of 1 mM
polyethylenimine (Sigma) in OptiMEM (Invitrogen). This
transfection mixture was replaced 4 h later with 15 ml of
normal culture medium. The cells were then incubated for
48 h to allow virus production. After the incubation, the
medium was removed and centrifuged for 10 min at
2,600 x g. The supernatant was then passed through a
0.45 μm filter and this filtrate was used as the virus stock.
T47D cells were transduced with virus stock by overnight
incubation.
Cell migration assays
T47D cells were grown to confluence in chamber slides
(Ibidi). The confluent monolayer was scratched with a
sterile pipette tip and migration was followed by bright-
field imaging at 37 °C for 14 h using a Leica AF6000 live
cell imaging workstation and x40 objective. Multipoint
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revisiting allowed for parallel imaging of samples.
Average cell velocity was calculated using ImageJ
(NIH). For quantification of Golgi polarization, cells
were fixed 1 h after making the scratch and stained
for giantin. Cell polarization was assessed by dividing
cells into quadrants centered on the nucleus. Cells
were judged to have polarized if the majority of their
Golgi apparatus resided within the quadrant facing
the scratch edge.
Cell invasion assays
Invasion of T47D cells was quantified using BD BioCoat
Matrigel Invasion Chambers (BD Biosciences) according
to the manufacturer’s protocol. Briefly, T47D cells in
serum-free medium were plated at 1 × 105 cells per
chamber. Medium containing 10% fetal bovine serum
was used as the chemoattractant in the lower chamber.
After 24 h, non-invaded cells were removed from the
upper chamber using a cotton swab. Cells that invaded
through the Matrigel to the bottom of the insert were
fixed and stained by incubation with Diff-Quick (BD
Biosciences) for 10 min. These stained cells were washed
with PBS, air-dried and counted.
Statistical analysis
Analysis of statistical significance was performed using
GraphPad Prism software. Comparison of two sample
experiments was by paired, two-tailed Student’s t-test.
Analysis of multiple samples was made using one-way
ANOVA. For comparisons to a control, Dunnett’s post
hoc test was used, whereas comparisons between all
samples employed Tukey’s post hoc test.
Results
RhoBTBs control the expression of METTL7 isoforms
Our previous microarray screen identified METTL7A as
a potential target of RhoBTB2-mediated transcriptional
regulation [16]. To validate this, we used two independent
siRNAs to silence RhoBTB2 in HeLa cells and measured
METTL7A expression by RT-PCR. We also examined the
expression of METTL7B, a closely-related protein that
shares 59% sequence identity with METTL7A. Silencing
of RhoBTB2 reduced the expression of METTL7A by
Fig. 1 RhoBTBs differentially control METTL7 expression. a HeLa cells were transfected with siRNAs targeting RhoBTB1 or RhoBTB2, or the lamin
siRNA control. Two independent siRNAs were used for each target. The efficiency of these siRNAs in HeLa cells was quantified in our previous
study [16]. After 48 h, RNA was prepared from the cells and the expression of METTL7A was quantified by RT-PCR. Silencing of RhoBTB2 significantly
reduced the expression of METTL7A. b Expression of METTL7B was quantified in the same samples. Silencing of RhoBTB1 significantly reduced the
expression of METTL7B. Data are means ± SEM (n = 3). Data were normalized to mock-transfected HeLa cells. Comparisons are to the lamin siRNA
control; *P <0.05, **P <0.01, ****P <0.0001
Fig. 2 Silencing of RhoBTB1 causes Golgi fragmentation. HeLa cells
were transfected with siRNAs targeting RhoBTB1 or RhoBTB2. After 48 h,
the cells were fixed and stained for the Golgi marker giantin (green).
a Shows representative images of normal and RhoBTB1 depleted cells.
Bar = 10 μm. b Silencing of RhoBTB1 caused a marked and significant
fragmentation of the Golgi. Data are means ± SEM (n= 3). Data were
normalized to mock-transfected HeLa cells. Comparisons are to the
lamin siRNA control; *P<0.05, **P<0.01
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approximately 30% (Fig. 1a). Previously, we showed that
both RhoBTB1 and RhoBTB2 are required for expression
of CXCL14 [16]; however, silencing of RhoBTB1 had no
effect on METTLA expression (Fig. 1b). Interestingly,
RhoBTB1 instead regulated the expression of METTL7B
(Fig. 1b). We conclude that the two human METTL7 iso-
forms are differentially regulated by these two RhoBTBs.
RhoBTB1 regulates Golgi integrity
METTL7B was originally identified as a Golgi-associated
methyltransferase of unknown function [20]. Previous
work has shown that inhibition of cellular methylation
leads to fragmentation of Golgi, although the identity of
the methyltransferase involved is unknown [21]. We hy-
pothesized that the RhoBTBs might act through METTL7
Fig. 3 RhoBTB1 regulates Golgi integrity through METTL7 proteins. a-b HeLa cells were transfected with siRNAs targeting METTL7A, METTLB or
both. After 48 h, RNA was prepared from the cells and the expression of each METTL7 was quantified by RT-PCR. Data are means ± SEM (n = 3).
c HeLa cells were transfected with the same siRNAs and fixed and stained for the Golgi marker giantin. Silencing of either methyltransferase
caused a marked and significant fragmentation of the Golgi. Data are means ± SEM (n = 3). Comparisons are to the control lamin siRNA. d Shows
representative images of the cells. Golgi are stained in green; nuclei in blue. e HeLa cells were transfected with siRNAs targeting RhoBTB1 and with
plasmids expressing myc-tagged METTL7A or METTL7B. After 48 h, the cells were fixed and stained for the Golgi marker giantin (green) and for
the transfected methyltransferases (red). Bars = 10 μm. f Quantification of transfected cells showed that expression of either METTL7 rescued Golgi
morphology in cells depleted of RhoBTB1. Data are means ± SEM (n = 3); comparisons are as indicated. *P <0.05; **P <0.01, ***P <0.001, ****P <0.0001
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proteins to control some aspect of Golgi function. To
examine this, we silenced RhoBTB1 and RhoBTB2 expres-
sion and examined the basic morphology of the Golgi by
staining cells for the well-characterized Golgi marker,
giantin. In control cells, the Golgi was present as a charac-
teristic ribbon situated next to the nucleus. Silencing of
RhoBTB2 had a negligible effect on Golgi morphology;
however, silencing of RhoBTB1 caused profound frag-
mentation of the Golgi (Fig. 2a, b).
RhoBTB1 regulates Golgi integrity through METTL7B
We designed specific siRNAs to each METTL7 isoform
to allow us to investigate their role in the regulation of
Golgi integrity (Fig. 3a, b). Interestingly, silencing of
either isoform caused significant fragmentation of the
Golgi (Fig. 3c, d). This raised the possibility that down-
regulation of METTL7B might underlie the effects of
RhoBTB1 depletion on Golgi integrity. To test this, we
silenced RhoBTB1 and then restored METTL7B expres-
sion by transfection. This re-expression of METTL7B
was able to significantly rescue Golgi integrity (Fig. 3e, f ).
Intriguingly, expression of METTL7A also promoted
recue of normal Golgi morphology (Fig. 3e, f ). We con-
clude that the effects of RhoBTB1 depletion on Golgi
integrity are mediated through the consequent reduced
expression of METTL7B, but that METTL7A overexpres-
sion can substitute for this activity.
METTL7B has been reported as being localized to the
Golgi [20], whereas METTL7A (a.k.a. AAM-B) has pre-
viously been shown to localize to the endoplasmic
reticulum (ER) and to lipid droplets [22]. It was unclear
why both isoforms should affect Golgi morphology,
given their different locations. We examined the cellular
localization of both proteins. In contrast to the previous
report [20], we found that both METTL7s localized to
the ER in HeLa cells, with no apparent Golgi localization
(Fig. 4a, b). We conclude that the relevant target(s) for
METTL7 action is likely to be an ER resident protein,
or a protein that actively shuttles between the two
compartments.
RhoBTB1 is expression is downregulated in breast cancer
cell lines
Many studies have reported downregulation of RhoBTB2
expression in breast cancer, most commonly due to
methylation of the RhoBTB2 promoter [7, 10, 11, 23, 24].
We examined the relative expression of RhoBTB1 and
RhoBTB2 in a selection of human breast cancer cell lines
(MDA-MB-231, T47D, MCF7) in comparison to two well-
characterized normal human mammary epithelial cell
lines – MCF10A [25] and HMT-3522 S1 [26]. All three
breast cancer cell lines had reduced RhoBTB1 expression
(Fig. 5a). T47D and MDA-MB-231 cells also showed re-
duced expression of RhoBTB2, whereas expression was
normal in MCF7 cells (Fig. 5b). We examined the expres-
sion of METTL7A and METTL7B in the same cell lines.
Interestingly, both isoforms showed reduced expression
in the breast cancer cell lines, with T47D cells having
the lowest overall expression of METTL7 isoforms
(Fig. 5c, d). T47D cells have previously been shown to
undergone loss of RhoBTB2 expression [7]. They also
had the lowest expression of RhoBTB1 (Fig. 5a). Intri-
guingly, whereas the normal mammary cell lines had a
compact Golgi ribbon, T47D cells showed extreme
fragmentation of the Golgi (Figs. 5e, 6b), raising the
possibility of a functional link between loss of RhoBTB1
expression and Golgi morphology in this breast cancer
line.
Restoration of RhoBTB1 expression restores normal Golgi
morphology to T47D cells and inhibits invasion
To explore the effect of loss of RhoBTB1 expression on
Golgi integrity in T47D cells, we restored RhoBTB1
Fig. 4 METTL7 proteins are localized to the endoplasmic reticulum.
a HeLa cells were transfected with myc-tagged METTL7A (green) and
fixed and stained for the ER marker calnexin (red) or the Golgi marker
giantin (red). METTL7A showed no significant localization to the Golgi,
but instead was present in the ER and also to small punctate structures.
b The experiment was repeated with myc-tagged METTL7B. METTL7B
also localized to the ER and small puncta. Bar = 10 μm
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expression using lentiviral transduction. The resultant
stable cell line had near normal levels of RhoBTB1, but
still had dramatically lower levels of RhoBTB2 (Fig. 6a).
Restoration of RhoBTB1 expression led to a significant
rescue of Golgi integrity (Fig. 6b).
Fragmentation of the Golgi has little effect on the rate
of protein secretion in cells [27]. In keeping with this,
we saw no apparent change in the rate of trafficking of
VSV-G through the secretory pathway in cells depleted
of RhoBTB1 (data not shown). One proposed function
of the Golgi ribbon structure is to facilitate the cellular
localization of this organelle. Polarized epithelial cells
orientate their Golgi towards the apical surface of the
cell, and this is important for polarized secretion and for
maintenance of the apical-basolateral axis [28]. In mi-
grating cells, the Golgi is polarized towards the leading
edge of the cell in the majority of cell types and this re-
inforces directional migration [29]. Dysregulation of cell
polarity pathways is an important component in the con-
version of cancer cells into a migratory, invasive pheno-
type. We examined whether restoration of RhoBTB1
expression and normalization of Golgi morphology would
affect these processes in T47D breast cancer cells. We
used a scratch migration assay to measure Golgi po-
larization and the directional migration of cells. T47D
cells failed to polarize their Golgi effectively in the
scratch assay; whereas restoration of RhoBTB1 expres-
sion resulted in strong polarization of the Golgi to-
wards the migration front (Fig. 6d). Restoration of
RhoBTB1 expression had no effect on T47D cell migra-
tion, however, suggesting that the Golgi fragmentation
observed in T47D cells does not affect their migration
in 2D (Fig. 6e). We next examined the invasive capacity
of these cells. A critical early stage in breast cancer pro-
gression is breakdown of the highly polarized organization
of cells in a mammary duct and their invasion through the
basement lamina and into the surrounding stroma. We
measured the ability of T47D breast cancer cells to invade
through a 3D layer of extracellular matrix that mimics the
composition of the basement lamina [30]. Restoration of
RhoBTB1 expression dramatically inhibited cell invasion
(Fig. 6f). We conclude that loss of RhoBTB1 expression in
Fig. 5 RhoBTB1 is expression is downregulated in breast cancer cell lines. a-d The expression of RhoBTB1, RhoBTB2, METTL7A and METTL7B was
measured by RT-PCR in three well-characterized breast cancer cell lines: MDA-MB-231, T47D and MCF7. Expression was compared with two
well-characterized normal mammary epithelial cell lines: MCF-10A and HMT-S1. Data are means ± SEM (n = 3). Data were normalized to HeLa
cell samples. Comparisons are to the MCF10A control; *P <0.05; **P <0.01, ***P <0.001, ****P <0.0001. All three breast cancer lines showed a
markedly reduced RhoBTB1 expression, as well as reduction in expression of METTL7A and METTL7B. T47D cells had the lowest levels of both
RhoBTB1 and RhoBTB2. e the breast cancer cell lines were fixed and stained for giantin (green) and Golgi morphology compared to the normal
mammary epithelial HMT-S1 line. T47D cells showed marked fragmentation of the Golgi. Bar = 10 μm
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T47D breast cancer cells contributes to a pro-invasion
phenotype. Our hypothesis is that this is a result of re-
duced METTL7B expression, leading to Golgi fragmenta-
tion and a breakdown of normal cell polarity.
Discussion
RhoBTB proteins are highly unusual members of the
RhoGTPase family. Their multidomain structure makes
them atypical; however, they are present in a wide range
of organisms, including the social amoeba Dictyostelium
discoideum, where they were first identified [31]. We still
know very little about the cellular functions of RhoBTB1
and 2. Most progress has come from investigating the
function of their twin BTB domains [6]. In many pro-
teins, the BTB domain functions to recruit the Cul3 ubi-
quitin ligase [32]. RhoBTB2 can bind Cul3 through its
first BTB domain [33, 34]. RhoBTB2 itself is a target of
ubiquitylation by this complex, leading to its subsequent
degradation by the proteasome [34]. This raises the pos-
sibility of a role for the RhoBTB2/Cul3 complex in regu-
lating the turnover of other cellular proteins, although
no targets of RhoBTB2/Cul3 mediated ubiquitylation
have yet been identified.
BTB domains are also frequently found in transcrip-
tional regulators, where they have a number of roles, in-
cluding the recruitment of transcriptional co-repressors
[35]. Previously, we showed that RhoBTB2 controls the
expression of the CXCL14 chemokine in epithelial cells
[16]. Here were show that the METTL7 enzymes are
targets of transcriptional control by RhoBTB1 and 2.
CXCL14 expression requires both RhoBTB1 and 2 [16],
whereas the two RhoBTBs had specific roles in regulating
the METTL7 enzymes, with RhoBTB2 regulating expres-
sion of METTL7A and RhoBTB1 regulating METTL7B.
The RhoBTBs dimerize through their BTB domains, and
can form both homo- and heterodimers [33]. It seems
likely these different dimer pairs have different transcrip-
tional targets. This becomes important when considering
the effects of the downregulation of RhoBTB1 and 2 in
cancer cells, where loss of one isoform could potentially
increase homodimer concentration of the other, in
addition to the simpler effects of reducing its own
concentration.
We show here that RhoBTB1 regulates Golgi integrity.
Interestingly, the third RhoBTB family member, RhoBTB3,
has also been shown to regulate Golgi function. RhoBTB3
is only weakly-related to RhoBTB1 and 2, but shares a
similar domain organization [6]. RhoBTB3 is a Golgi-
localized protein and binds to directly to the secretory
pathway regulator Rab9 to mediate trafficking from the
endoplasmic reticulum to the Golgi [36]. RhoBTB3 silen-
cing has been reported to lead to enlargement of the Golgi
[36] and in a later study to cause Golgi fragmentation[37]
The mechanism by which RhoBTB3 affects Golgi integrity
Fig. 6 Restoration of RhoBTB1 expression restores normal Golgi
morphology to T47D cells and inhibits invasion. a T47D cells were
transduced with a lentiviral RhoBTB1 construct to restore RhoBTB1
expression. Expression of RhoBTB1 and RhoBTB2 was measured by RT-
PCR. Transduction with RhoBTB1 restored expression to near normal levels,
but did not affect expression of RhoBTB2. Data are means ± SEM (n= 2).
b Cells were fixed and stained for the Golgi marker giantin. Restoration of
RhoBTB1 expression caused a significant reduction in Golgi fragmentation.
Data are means ± SEM (n= 3). c shows representative images of control
T47D cells, and the T47D line expressing RhoBTB1. Golgi are stained in
green; nuclei in blue. Bar = 10 μm. d T47D cells were grown to confluence
and cell migration was initiated by scratching the coverslip to remove a
strip of cells. Cells were fixed at 1 h and stained for Golgi (giantin, green).
The dashed line indicates the cell front. Quantification of Golgi polarization
showed that T47D cells had little ability to polarize (25% polarization
corresponds to random orientation in this assay); whereas restoration of
RhoBTB1 supported robust polarization. Data are means ± SEM (n= 3).
e Migration was measured in the same assay over 14 h. Data are
means ± SEM (n= 3). Restoration of RhoBTB1 expression had no effect
on T47D cell migration in 2D. f T47D invasion through 3D extracellular
matrix was measured in Matrigel invasion chambers over 24 h. Restoration
of RhoBTB1 expression markedly reduced invasive capacity. Data are
means ± SEM (n= 3). *P<0.05; **P<0.01, ***P<0.001, ****P<0.0001
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has not been reported. We show here that RhoBTB1
controls Golgi integrity through regulation of the expres-
sion of METTL7B. The downstream targets of the poorly-
characterized METTL7 enzymes are unknown. Both
contain an N-terminal transmembrane domain and a C-
terminal methyltransferase domain, predicted to lie on the
cytoplasmic face. Interestingly, METTL7B undergoes ar-
ginine dimethylation [20], raising the possibility of auto-
methylation. Depletion of either METTL7A or B caused
Golgi fragmentation (Fig. 3c) and METTL7A overexpres-
sion was able to rescue the effects of depletion of
METTL7B (Fig. 3e). This suggests that the two proteins
have overlapping functions in regulating Golgi integrity.
Silencing of RhoBTB2 did not cause significant Golgi frag-
mentation (Fig. 2b), despite a reduction in METTL7A ex-
pression (Fig. 1a). The effects of RhoBTB2 on METTL7A
are less pronounced than those of RhoBTB1 on
METTL7B, at least in HeLa cells (Fig. 1). It is possible that
RhoBTB2 might affect Golgi integrity in other cell types,
perhaps where METTL7A is the more dominant isoform.
In vertebrates, the Golgi apparatus is organized into a
compact ribbon structure, typically located next to the
nucleus [38]. This organization depends on the constant
action of the motor protein dynein and on the functions
of Golgi structural proteins [29, 38]. Surprisingly, Golgi
ribbon structure is not requisite for the functioning of
the secretory pathway. In plants, individual Golgi stacks
are scattered throughout the cytosol, and in the yeast
Saccharomyces cerevisiae, the Golgi is composed of
dispersed, isolated cisternae [38, 39]. In vertebrate cells,
treatments that fragment the Golgi do not affect the rate
of protein secretion [40, 41]. Instead, the organized
Golgi ribbon structure seems to be important for verte-
brate cell polarization. In polarized epithelial cells, the
Golgi is orientated towards the apical surface [28]. In
most migrating vertebrate cells, the Golgi is orientated
towards the leading edge [29, 42]. These observations
suggest that a polarized Golgi ribbon may facilitate po-
larized secretion. In polarized epithelial cells, this would
support apical/basolateral polarity, and in migrating
cells, it would contribute to directional movement. In
keeping with this, recent work supports a role for the
Golgi in the polarized delivery of active Cdc42 to the
leading edge of migrating cells [43]. Fragmentation of
the Golgi has previously been shown to inhibit the mi-
gration of HeLa cells [27]. Here we find that the loss of
expression of RhoBTB1 in T47D breast cancer cells is
linked to fragmentation of the Golgi. This can be res-
cued by re-expression of RhoBTB1; however, this has no
effect on migration of these cells in 2D (Fig. 6e). Instead,
we found that re-expression of RhoBTB1 in T47D breast
cancer cells strongly inhibited their invasive capacity in
3D (Fig. 6f ). The initial stages of breast cancer progres-
sion involve loss of apical-basolateral polarity and invasion
through the basement lamina. We propose that loss of
RhoBTB1 early in breast cancer development promotes
loss of normal epithelial polarity through reduced
METTL7B expression and Golgi fragmentation. We
propose that this then contributes to the switch to an
invasive phenotype.
Conclusions
RhoBTB1 is important for maintaining the integrity of
the Golgi, through regulation of the expression of
METTL7B. In keeping with this, loss of RhoBTB1 ex-
pression leads to fragmentation of the Golgi. Restoration
of normal RhoBTB1 levels to T47D breast cancer cells
restores Golgi integrity and leads to a dramatic decrease
in their invasive capacity.
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